Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity follow-up after Norovirus GI.1/GII.4 bivalent vaccine
2016-004288-37Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2017
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of human norovirus bivalent (GI.1/GII.4) vaccine in Noroviral gastroenteritis, sponsored by Takeda. Started Feb 2017; status: completed.
02
Drugs
human norovirus bivalent (GI.1/GII.4) vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on 2016-004288-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004288-37.